Peptide Receptor
Radionuclide
Therapy(Pro-Drug)
Neuroendocrine tumor
SSTR2
PRRT, PDC, Pro-drug
solid cancer
FAP-α
CBT-004
CNP
Achondrogenesis
NPR-B
CBT-005
Project Code
Target
Indicant
MOA & Molecule Type
Phase 3
Phase 2
Phase 1
Preclinical
Peptide Receptor
Radionuclide Therapy
Renal cancer
CAIX
CBT-001
Late
Discovery
Pipeline
Early
Discovery
Target: SSTR2
Indicant: Neuroendocrine tumor
MOA & Molecule Type: Peptide Receptor Radionuclide Therapy
Development stage: R&D
Summary: SSTR2 (Somatostatin Receptor 2) is a membrane protein present in the cell membrane that recognizes Somatostatin (peptide hormone) as a signal and regulates the secretion of hormones. SSTR2 is a target for neuroendocrine tumor treatments, and a representative treatment is Lutathera, a PRRT-based neuroendocrine tumor treatment. We designed a treatment with a Pro-Drug structure and secured a peptide that can bind to FAP-α with high expression around cancer cells. After binding to FAP-α, the peptide was isolated from the treatment and was developed to act only on cancer cells expressing SSTR2. Our company substance can lower toxicity to normal cells and increase specificity to cancer cells compared to Lutathera.
CBT-002
Kidney Cancer
Neuroendocrine Tumor
Solid Cancer
Achondroplasia
Project Code
Target
Indicant
MOA & Molecule Type
Phase 3
Phase 2
Phase 1
Preclinical
Peptide Receptor
Radionuclide Therapy
CAIX
CBT-001
Late
Discovery
Peptide Receptor
Radionuclide
Therapy(Pro-Drug)
SSTR2
PRRT, PDC, Pro-drug
FAP-α
CBT-004
CNP
NPR-B
CBT-005
Pipeline
Early
Discovery